CStone Pharmaceuticals
CSPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -83.8% | -39.8% | 25.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -187.6% | 44.5% | 67.7% | 74.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -560.5% | -66.9% | -1.4% | -173.7% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -546.4% | -69.9% | 6.2% | -78.1% |
| EPS | -0.1 | -0.084 | 0.01 | -0.124 |
| % Growth | -19.3% | -938% | 108.1% | – |
| EPS Diluted | -0.1 | -0.084 | 0.012 | -0.124 |
| Weighted Avg Shares Out | 1 | 1 | 2 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -538.3% | -55.7% | 1.3% | -169.2% |